摘要
目的观察普米克令舒联合可必特雾化吸入治疗婴幼儿喘息性肺炎的临床疗效。方法选择喘息性肺炎婴幼儿106例,按照自愿的原则,随机均分为常规组与雾化组,常规组给予各项常规治疗,雾化组在常规治疗的基础上给予普米克令舒联合可必特雾化吸入治疗,比较两组患儿喘鸣音消失天数、咳嗽明显减轻天数和肺部啰音消失天数;治疗7d后比较两组患儿临床疗效。结果雾化组临床疗效好于对照组,在上述方面比较,差异具有统计学意义(P<0.05)。结论治疗婴幼儿喘息性肺炎时,应加用普米克令舒联合可必特雾化吸入治疗,可提高临床疗效。
Objective To observe the clinical effect of Pulmicort combined with Compound Ipratropium Bromide Aerosol in treating the infant asthmatic pneumonia by the inhalation therapy.Methods Collect 106 asthmatic pneumonia infants,according to the principle of voluntary,53 infants were divided into the conventional group with the conventional treatment,53 infants were divided into the spray group with the conventional treatment and the inhalation therapy by Pulmicort combined with Compound Ipratropium Bromide Aerosol,compare the days of wheezing disappearance,the days of coughing significantly alleviating,the days of pulmonary rales disappearance and the clinical effect after 7 days treatment.Results：The spray group＇s clinical effects were better than the conventional group＇s,there was a statistical significant（P0.05） in the above aspects after 7 days treatment.Conclusion When we treat the infant asthmatic pneumonia,we should add the inhalation therapy by Pulmicort combined with Compound Ipratropium Bromide Aerosol,it should improve the clinical effect.
出处
《当代医学》
2011年第11期142-143,共2页
Contemporary Medicine
关键词
普米克令舒
可必特
婴幼儿
喘息性肺炎
Pulmicort
Compound Ipratropium Bromide Aerosol
Infant
Asthmatic pneumonia
